Mar Cor, a division of Cantel Medical, already provides clients in the pharmaceutical, semiconductor manufacturing and research laboratories with water purification and filtration equipment and this acquisition looks to strengthen their position in the pure water business. The acquisition will enable Mar Cor to better compete against other suppliers of water purification systems such as Millipore, Pall and Sartorius. The addition of GE's dialysis water business will expand Cantel's water treatment division by 50 per cent and the company says it will increase the density and efficiency of its service delivery. "We saw this [acquisition] as a distinctive opportunity to secure a leadership position in the medical water industry and create a platform with which to expand into other areas of life science and commercial/industrial applications," said Curtis Weitnauer, president of Mar Cor. "Each new clinic represents an opportunity for a complete water system, and each existing clinic represents a long term revenue opportunity as we support their operation with consumables, product enhancements and services." The acquisition will add GE's 510K-compliant ZyzaTech and 23G reverse osmosis (RO) water equipment technologies to Mar Cor's existing RO and electrodeionisation systems. 510k compliance allows medical devices that are equivalent to approved devices to be marketed and sold in the US without the need for pre market approval by the US Food and Drug Administration (FDA). The GE Dialysis business was part of Osmonics before its acquisition by GE in 2002. GE water dialysis employees will join Mar Cor and will be relocated along with the manufacturing capabilities to the Cantell Medical manufacturing facility in Minneapolis.
Mar Cor Purification has bought GE Water and Process Technologies' dialysis water business for $30.6m (€22.8m) to become the largest provider of dialysis water in the US, and plans to expand their presence in industrial life science markets.